Cargando…
New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment?
Autor principal: | Messori, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493241/ https://www.ncbi.nlm.nih.gov/pubmed/28717746 http://dx.doi.org/10.1200/JGO.2016.006361 |
Ejemplares similares
-
Which quality of life score is best for glaucoma patients and why?
por: Severn, Philip, et al.
Publicado: (2008) -
Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation?
por: Hübner, Yannis R., et al.
Publicado: (2023) -
Discussing and prescribing expensive unfunded anticancer drugs in Australia
por: Karikios, Deme John, et al.
Publicado: (2017) -
Erratum: Correction of the Text in the Article “Funding”: Incidence-Based versus Prevalence-Based Approaches on Measuring Disability-Adjusted Life Years for Injury
por: Park, Bohyun, et al.
Publicado: (2019) -
Locomotor play drives motor skill acquisition at the expense of growth: A life history trade-off
por: Berghänel, Andreas, et al.
Publicado: (2015)